Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of South Florida
With
OBJECTIVES: * Compare the response rates in pediatric cancer patients with treatment-related neurocognitive sequelae treated with dextroamphetamine-amphetamine (Adderall-XR®) vs methylphenidate (Concerta®). * Compare the durability of response at 12 weeks in patients who show a response at 3 weeks after treatment with these drugs. * Determine whether patients who have no response to one of these study drugs can respond to the other study drug. * Determine the prevalence of depression and possible response to neurostimulant therapy in this patient population. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral dextroamphetamine-amphetamine once daily for 3 weeks. Patients who achieve response (based on neurocognitive testing) continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm II after a 48-hour washout period. * Arm II: Patients receive oral methylphenidate once daily for 3 weeks. Responding patients continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm I after a 48-hour washout period. Depression and neurocognitive function are assessed at baseline, 3 weeks, and end of study. PROJECTED ACCRUAL: A total of 177 patients (approximately 88 per treatment arm) will be accrued for this study within 3 years.
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
